Valinor | $13,000,000 | (Dec 12, 2025)
Keeper | $4,000,000 | (Dec 12, 2025)
Cyphlens | $3,800,000 | (Dec 12, 2025)
BAKX Therapeutics
United States
- New York | Boston
- 18/11/2021
- Series A
- $25,000,000
We create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations
We have built an integrated & iterative platform based on knowledge, experimentation, and simulation that allows us to better interrogate and harness the power of regulated apoptosis
We are developing a suite of orally active therapeutics which can act as single agents or in combination with other oncology therapies to create better and lasting outcomes for cancer patients
- Industry Biotechnology
- Website https://bakxtx.com/
- LinkedIn https://www.linkedin.com/company/bakxtx/
Related People
Sree KantFounder
United States -
New York, New York
Life Sciences thought leader and executive. Former head of Corporate Development at Life Biosciences; Former head of partnering strategy for Pfizer. Former healthcare principal at Boston Consulting.
OnCorps AI | $55,000,000 | (Dec 12, 2025)
conveyd | $3,345,837 | (Dec 12, 2025)
Safebooks AI | $15,000,000 | (Dec 12, 2025)
Double (1) | $6,500,000 | (Dec 12, 2025)
Yonda | $15,000,000 | (Dec 12, 2025)
Medra | $52,000,000 | (Dec 12, 2025)
Cynch AI | $9,000,000 | (Dec 12, 2025)
Empromptu.ai | $2,000,000 | (Dec 11, 2025)